Epcoritamab shows best-in-class potential for DLBCL
Efficacy, safety in CAR T naive patients could challenge CD19 CAR Ts in diffuse large B cell lymphoma
The latest Phase II data from epcoritamab in diffuse large B cell lymphoma shows it may have best-in-class potential versus fellow anti-CD20 bispecific glofitamab, plus the potential to challenge autologous CD19-targeted CAR Ts on efficacy and milder safety.
Partners Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) presented data at the European Hematology Association (EHA) Annual Congress that showed CD20xCD3 bispecific epcoritamab had a higher objective response rate (ORR) and complete response (OR) rate in the EPCORE NHL-1 trial than glofitamab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) showed in Phase II data presented at the American Society of Clinical Oncology (ASCO) meeting. Both studies enrolled relapsed/refractory DLBCL patients...